Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PDGF-D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDGF-D Full-Length / Mature GFD Active Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View PDGFD Products |
| Gene Delivery | PDGF-D Promise-ORF / Lentivirus Full-length ORF for stable cell lines and receptor activation assays. |
View PDGFD Products |
| Benchmark Ab | Anti-PDGF-D Recombinant Antibody Recombinant positive control for binding and neutralization validation. |
View PDGFD Products |
| Validator | PDGF-D siRNA Set Target-specific knockdown verification in primary stromal cells. |
View PDGFD Products |
| Related Target A | PDGFRB (PDGF Receptor Beta) Cognate receptor mediating downstream stromal activation and angiogenesis. |
View PDGFRB Products |
| Related Target B | ST14 (Matriptase) Primary serine protease responsible for proteolytic cleavage and activation of PDGF-D. |
View ST14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing full-length latent PDGF-D from mature active GFD dimer | Separate offerings of latent FL-PDGF-D and mature active GFD homodimers, sequence-verified by MS. |
| Receptor binding specificity (PDGFRB vs PDGFRA) | High-purity PDGFRB and PDGFRA extracellular domains available for comparative SPR/BLI binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target knockdown and specificity checks. |
Live PDGF-D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDGF-D therapeutics is intensifying, with major players shifting focus from traditional multi-targeted TKIs to selective monoclonal antibodies, bispecifics, and trap molecules. As first-generation broad-spectrum kinase inhibitors face limitations due to off-target toxicities, the next wave of R&D is targeting the specific extracellular activation of PDGF-D to arrest tissue fibrosis and remodel the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Curagen, Boehringer Ingelheim | Renal Fibrosis, Solid Tumors | Neutralization Assay (Need mature active PDGF-D GFD dimer) |
| Bispecific Antibody | Innovent, Roche | Neovascular Macular Degeneration | Dual-binding validation (Need cross-reactive PDGF-D and VEGF proteins) |
| Protease Inhibitors | Academic Research Institutes | Oncological Metastasis | Cleavage Inhibition Assay (Need full-length latent PDGF-D with CUB domain) |